{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "DTIL",
  "name": "Precision BioSciences, Inc.",
  "url": "https://frontierpicks.com/dossiers/DTIL/",
  "json_url": "https://frontierpicks.com/dossiers/DTIL.json",
  "status": "WATCHLIST",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "First clinical evidence that a gene editor removes hepatitis-B cccDNA (EASL late-breaker, 2026-05-27, <1% remaining in one biopsy) is the whole story; the shares closed $7.47 on 2026-09-04, 19.5% under the $9.28 52-week high, with no company-dated catalyst until the guided year-end 2026 PBGENE-HBV and PBGENE-DMD updates and a runway that explicitly leans on the ATM.",
  "invalidation_trigger": "A weekly close below $6.50 hands back more than the full 10.3% three-month advance and breaks the post-EASL range; secondarily, the guided year-end 2026 PBGENE-HBV update slipping into 2027 at the ~2026-11-05 Q3 print, or material ATM issuance appearing with no data event to absorb it.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "rare-disease-gene-therapy",
    "precision-biotech-therapeutics",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Runway 'through 2028' is stated as resting on cash plus availability of the at-the-market facility (Q2 release, 2026-08-06) — equity issuance is part of the stated plan.",
    "Reported net loss includes non-cash warrant-liability remeasurement ($11.9M in Q2 2026) that widens when the share price rises; EPS versus consensus can be non-operational.",
    "No product revenue: Q2 2026 revenue was $0 against a compiled FY2026 consensus revenue of $13.48M.",
    "Sell-side coverage is thin — 5 analysts, compiled average target $29.4 versus a $20 median and a $60 high (stockanalysis.com, retrieved 2026-09-05)."
  ],
  "body_markdown": "## Current Thesis\n\nThe narrative on offer is a first-in-human claim, not a commercial one: that an ARCUS gene editor delivered by LNP can physically remove covalently closed circular DNA (cccDNA) from infected hepatocytes, which is the reservoir that makes chronic hepatitis B incurable with nucleoside analogues. That claim moved from preclinical to clinical on 2026-05-27, when paired liver-biopsy data from the Phase 1 ELIMINATE-B study were presented as a late-breaker at EASL in Barcelona (data cut 2026-05-04): in one patient dosed twice at 0.4 mg/kg, cccDNA-derived transcripts fell by 1 log with less than 1% of cccDNA remaining. Everything else in the equity — the $112.4 million cash pile at 2026-06-30, the second program in Duchenne, the $60 outlier price target — hangs off whether that mechanism repeats in more patients.\n\nWhere the story sits: the narrative is maturing — the cccDNA-elimination result was established on 2026-05-27 and has been priced for three months, the shares closed at $7.47 on 2026-09-04, 19.5% below the 52-week high of $9.28, RSI(14) at 51.1, and the company's own guidance puts the next PBGENE-HBV update at \"year-end 2026,\" so the window between now and then carries no company-dated event to refresh the bid. Fresh headlines did arrive in August (first DMD patient dosed 2026-08-24; partner data 2026-08-27) without producing a new high.\n\n## Bull Case\n\n- **Mechanism evidence, not surrogate**: liver biopsy in a treated patient showed a 1-log reduction in cccDNA-derived transcripts with <1% of cccDNA remaining after two 0.4 mg/kg doses — presented at EASL 2026 on 2026-05-27 and restated in the Q2 release of 2026-08-06. No other HBV program has published clinical biopsy evidence of direct cccDNA elimination.\n- **Breadth across the dose range**: 16 patients treated with 38 administrations across five cohorts spanning 0.2–0.8 mg/kg; HBsAg declines reported in 100% of treated patients, and pgRNA durably undetectable in 100% of patients with detectable baseline (Q2 2026 release, 2026-08-06).\n- **Tolerability so far**: no dose-limiting toxicities; LNP-related hypotension addressed with longer infusion duration and steroid co-administration (2026-08-06). For an in vivo liver-targeted editor, safety at repeat dosing is the gating item, and it has not gated yet.\n- **A second clinical asset**: first patient dosed in the Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD on 2026-08-24, in patients aged 2–7, with sites at Arkansas Children's Hospital and Washington University; initial safety data guided to year-end 2026.\n- **Funded past the next two readouts**: $112.4 million in cash, equivalents and restricted cash at 2026-06-30, with management stating runway through 2028 and sufficiency to reach both HBV and DMD data milestones. Operating expense fell year over year — R&D $12.4M (Q2 2025: $12.8M), G&A $6.8M (Q2 2025: $9.1M).\n- **Platform validation from a licensee**: iECURE's ECUR-506, built on an ARCUS nuclease, reported on 2026-08-27 a 74% reduction in annualized hyperammonemic crises and a 57% reduction in hyperammonemic events in low-dose OTC-HOPE cohorts, with dosing complete across all three cohorts.\n- **Sell-side is positioned above the tape**: H.C. Wainwright's Patrick Trucchio reiterated Buy with a $60 target on 2026-08-12; stockanalysis.com showed a 5-analyst compiled average of $29.4 and a median of $20, low $18, when retrieved 2026-09-05.\n\n## Bear Case\n\n- **The mechanism headline rests on one biopsy**: the <1% cccDNA result is a single patient at one dose level. A sample of one supports no durability or dose-response conclusion, and the year-end update is where it either replicates across cohorts or does not.\n- **Declines are not seroclearance**: \"substantial HBsAg declines in 100% of patients\" is not functional cure, which requires sustained HBsAg loss off treatment. The gap between those two endpoints is where most HBV programs have historically stalled.\n- **The runway includes selling stock**: the Q2 release dated 2026-08-06 frames runway through 2028 as resting on existing cash, operating discipline *and* availability of the at-the-market facility. Issuance is part of the stated plan rather than a contingency, and a rising tape is the condition under which an ATM is most usable.\n- **The loss line is levered to the share price**: Q2 2026 net loss of $32.7 million, or $(1.26) per share, versus $23.5 million, or $(2.13), in Q2 2025, and the widening was driven by an $11.9 million non-cash warrant-liability remeasurement tied to stock appreciation. The per-share loss halved while the dollar loss grew, which is what a materially larger share count does to the arithmetic (inference from the two reported figures).\n- **The print missed**: $(1.26) against the $(0.81) consensus on 2026-08-06.\n- **The revenue line is a promise**: Q2 2026 revenue was $0 (Q2 2025: under $0.1M), against a compiled FY2026 consensus revenue of $13.48M and FY2026 consensus EPS of $(3.87) (stockanalysis.com, 2026-09-05). Whatever milestone or license payment that consensus assumes was not in the June quarter.\n- **Coverage is thin and dispersed**: five analysts, with a $60 high against an $18 low — a range that says the modelled outcomes are binary rather than that the name is well-covered.\n\n## Setup & Price Structure\n\nThe 2026-09-04 close was $7.47, 19.5% under the 52-week high of $9.28, with a three-month price change of +10.3% and RSI(14) at 51.1 — mid-range momentum, no extension in either direction. The tape has spent the post-EASL period digesting rather than trending: the August news flow (DMD first dose 2026-08-24, licensee data 2026-08-27) did not produce a new high.\n\nPositioning and crowding observables, stated as observables: (1) the funding plan names the ATM explicitly, so incremental share supply is disclosed policy; (2) an $11.9 million warrant remeasurement in Q2 confirms a live warrant book whose mark rises with the stock, a structural overhang above current prices; (3) the compiled sell-side average of $29.4 sits roughly four times the last close, dragged by a single $60 target — dispersion of that size is not consensus, it is two different models; (4) the filings feed reviewed for this note showed no recent Form 4 activity, so insider-transaction evidence is absent rather than negative; (5) no theme cluster currently carries this name, so moves are single-name and there is no group bid to lean on; (6) no earnings date falls inside the next 30 days, removing the near-term event that usually concentrates flow.\n\nUpside structure is defined by $9.28: a weekly close above that level would mark the post-EASL range resolved upward and would be the first evidence of a new bid rather than rotation inside the existing range. Downside structure is defined by whether the three-month advance holds — a weekly close below $6.50 would hand back more than the entire 10.3% three-month gain and would leave the cccDNA story without price confirmation ahead of the year-end data.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-05 → 2026-10-05: no company-confirmed dated event.** The 30-day window is empty of scheduled company catalysts; the name drifts on sector beta and any unscheduled licensee or competitor headline.\n- **~2026-11-05 (est.)** — Q3 2026 results and business update (Q2 was reported 2026-08-06). Resolves how much of the ATM was used in the September quarter and whether cash burn tracks the runway-through-2028 claim.\n- **~2026-12-31 (est., company-guided \"year-end 2026\")** — next PBGENE-HBV clinical update from ELIMINATE-B. This is the event the equity is priced against: whether cccDNA elimination replicates beyond the single biopsy and whether any patient approaches HBsAg seroclearance.\n- **~2026-12-31 (est., company-guided \"year-end 2026\")** — initial PBGENE-DMD safety data from FUNCTION-DMD, first patient dosed 2026-08-24.\n- **Undated, within 2026** — management stated in May 2026 that further PBGENE-HBV data would be shared at hepatitis-focused medical conferences during the year; no specific conference date is confirmed in company communications reviewed for this note.\n\n## What Would Change Our Mind\n\nThe thesis breaks on the data first. A year-end 2026 PBGENE-HBV update that shows HBsAg declines plateauing without any patient approaching seroclearance, or a cccDNA result that fails to replicate the <1% biopsy finding across additional patients, removes the entire reason this equity carries a $60 outlier target. A dose-limiting toxicity or a second hypotension event that forces a protocol hold would do the same faster.\n\nOn price, the gradeable condition is a weekly close below $6.50: that gives back more than the full 10.3% three-month advance and would show the post-EASL range failing without a data event to blame. The secondary condition is dilution arriving without a catalyst to absorb it — a Q3 report (~2026-11-05 est.) showing material ATM issuance at prices near the current tape, in a name whose runway statement already contemplates that issuance.\n\nThe third break is the calendar itself: the year-end guidance is the only company-dated resolver, and guidance that slips into 2027 at the Q3 print would extend an unfunded-attention window by another quarter.\n\nConfirming evidence would run the other way: a weekly close above $9.28, replication of the cccDNA biopsy result in additional patients, or a second covering analyst marking to the mechanism rather than to the model.\n\n## Correlation Notes\n\n- This is a single-name setup. No current theme cluster carries DTIL, so its beta comes from small-cap clinical-stage biotech risk appetite (XBI-type flow) rather than from an AI or thematic complex; funding conditions for pre-revenue biotech are the dominant macro input.\n- Read-through runs both ways with the in vivo gene-editing group (Intellia, Beam and peers): a safety event in any LNP-delivered liver editor would be read across to ELIMINATE-B regardless of construct, and a clean competitor safety update supports the delivery thesis generally.\n- The HBV functional-cure field is contested by siRNA and antisense approaches; a strong late-stage readout from a competing HBsAg-lowering program is not obviously bullish or bearish for DTIL, because the differentiator claimed here is the cccDNA reservoir, not HBsAg alone.\n- ARCUS licensee news is a genuine correlated input: iECURE's 2026-08-27 OTC-HOPE update is platform evidence for the nuclease, not for PBGENE-HBV's delivery or dosing.\n- The warrant liability creates an internal correlation between share price and reported loss — a rising price mechanically widens GAAP net loss, so headline EPS comparisons against consensus are a poor read on operations in any quarter where the stock moved.",
  "first_seen": "2026-09-03",
  "last_analyzed": "2026-09-06T08:07:54+00:00",
  "last_synthesized": "2026-09-05",
  "last_update_source": "research_universe",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}